LIGHTNING RELEASES — Arlington, Virginia, Biotivia, May 8th, 2014. Dr David Sinclair fought a lonely battle for 5 years. As the Harvard scientist who discovered the health benefits of Resveratrol, a molecule found in red wine grapes, Sinclair’s work was dismissed by his critics. Now with thousands of scientific studies confirming his claims, Sinclair is getting the recognition he deserves. 

Time Magazine just added Dr Sinclair to their list of 100 Most Influential persons, and in December of last year David and a team of fellow scientists from Harvard, MIT, The National Institutes of Health and UNSW announced in the journal Nature that they have discovered that a coenzyme called NAD+ is able to reverse muscle aging by the equivalent of more than 30 human years by restoring communication between the cells’ nuclear and mitochondrial DNA.

Sinclair discovered that Resveratrol activates a class of human genes called sirtuins. The Sirt 1 gene has been shown to exert a chemoprotective effect against an array of chronic illnesses, including Type 2 Diabetes, some cancers and cardiovascular diseases. In fact Transmax resveratrol, the active form of the molecule, has been shown to mimic many of the beneficial effects of exercise and a low calorie diet. 

On his Harvard Medical School webpage, Dr Sinclair and colleagues are credited with identifying a cause of aging that is potentially reversible through supplementation with compounds such as Resveratrol and NAD+.

The discovery of NAD+ won the Nobel Prize for the three scientists decades ago. Last year David Sinclair unearthed its ability to reverse aging in the mitochondria of the living cell, and Dr Betz at Biotivia has made these findings available to the general public. 

James Betz is the founder and Chief Science Officer of Biotivia Labs, a company which engages in scientific research of functional plant based preventatives and treatments for Diabetes, Cancer, Heart Disease and Dementia, and which supplies the medical research community with purified concentrates and extracts of natural compounds. Resveratrol and other Sirtuin activators have been the key focus of Biotivia for the past 10 years. According to Betz: “Dr Sinclair’s Time Magazine honor is well deserved. David has made a world changing contribution to human health.” 

Betz went on to say: “Our NAD+ research program has put Biotivia far ahead in the development of NAD+ health and longevity bioceuticals. Mitotrans, the first NAD+ health supplement treatment, will be on the market in two weeks, and our NAD+ maintenance supplement is in the final development phase” Betz went on to say: “Biotivia will announce a partnership with a world class university research team very soon which will expand our research and development capabilities in this area. This collaboration will greatly accelerate development of new, efficacious and safe alternatives to many of the major pharmaceuticals now dominating the market.”

Web pages referred to:

Dr David Sinclair. Harvard Medical School.

Dr David Sinclair. Time Magazine article.

NAD+ Mitotrans health supplement. Biotivia.

About Biotivia

Biotivia Longevity Bioceuticals, LLC is a leading formulator and manufacturer of high potency bioceutical supplements for the medical, consumer and functional food markets. The company offers products designed to address specific biological processes and to modulate cellular and genetic pathways known to improve health and foster vitality.

James Betz, CEO and Chief Science Officer, along with his premier team of international longevity research and development scientists, has focused on a class of polyphenolic compounds called stilbenes, which include Resveratrol, Pterostilbene, Polydatin and their metabolites. These entirely natural compounds have demonstrated uniquely beneficial health and wellness properties. Biotivia created the first high-potency Resveratrol and Pterostilbene supplements, and continues to support clinical research on this molecule at university medical schools worldwide. James Betz recently authored a paper on Resveratrol and Diabetes which has been published in the peer reviewed journal European Endocrinology.

Contact for more information:

Cristina Sebastian
Biotivia LLC
2503 D N. Harrison St.
Ste. 13
Arlington, Virginia VA 22207
email: [email protected]

This story was originally published by American Banking News ( and is the sole property of American Banking News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.